KEY:NYSEKeyCorp Analysis
Data as of 2026-05-20 - not real-time
$20.92
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
KeyCorp trades around $20.92, sitting below its 20‑day SMA of $21.58 and facing a bearish MACD histogram, while the RSI of 43 suggests neutral momentum. Volume is increasing and the 30‑day volatility of roughly 21% combined with a beta near 1.0 points to market‑aligned risk, yet the stock remains above the identified support of $20.69 and below the resistance at $22.43. Fundamentally, the bank delivered a 12% revenue increase YoY and a striking 33% EPS jump, beating expectations and prompting analysts to upgrade to a "buy" consensus with a median target of $24. The dividend yield of 3.9% and a 50% payout ratio are supported by robust operating cash flow, indicating sustainability. However, the DCF fair‑value estimate of $17.15 places the current price in a slight premium, while a PE of 12.8 is well under the industry average of 16.5, suggesting a mixed valuation picture.
Strategic moves such as the acquisition of Clearwater UK and a potential Moody's rating upgrade broaden geographic exposure and could enhance the middle‑market M&A franchise, providing a catalyst for upside. The combination of solid dividend income, growth‑oriented earnings, and a favorable analyst outlook outweighs the moderate sector and regulatory risks, positioning KeyCorp as a compelling hold‑to‑buy opportunity across medium to long horizons.
Strategic moves such as the acquisition of Clearwater UK and a potential Moody's rating upgrade broaden geographic exposure and could enhance the middle‑market M&A franchise, providing a catalyst for upside. The combination of solid dividend income, growth‑oriented earnings, and a favorable analyst outlook outweighs the moderate sector and regulatory risks, positioning KeyCorp as a compelling hold‑to‑buy opportunity across medium to long horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term SMA and bearish MACD signal
- Neutral RSI and proximity to support level
- Increasing volume but limited upside in near term
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Earnings beat with strong revenue and EPS growth
- Analyst consensus "buy" with median target $24
- High dividend yield and sustainable payout
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strategic European acquisition expanding M&A franchise
- Potential Moody's rating upgrade improving credit perception
- Blend of value metrics (low PE) and growth prospects
Key Metrics & Analysis
Financial Health
Revenue Growth11.80%
Profit Margin27.02%
P/E Ratio12.8
ROE9.98%
ROA1.03%
P/B Ratio1.3
Op. Cash Flow$2.3B
Industry P/E16.5
Technical Analysis
TrendBullish
RSI42.9
Support$20.69
Resistance$22.43
MA 20$21.59
MA 50$20.85
MA 200$19.82
MACDBearish
VolumeIncreasing
Fear & Greed Index89.18
Valuation
Fair Value$17.15
Target Price$24.97
Upside/Downside19.38%
GradeFair
TypeBlend
Dividend Yield3.92%
Risk Assessment
Beta1.04
Volatility21.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.